A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.

نویسندگان

  • Laura R Saunders
  • Alexander J Bankovich
  • Wade C Anderson
  • Monette A Aujay
  • Sheila Bheddah
  • KristenAnn Black
  • Radhika Desai
  • Paul A Escarpe
  • Johannes Hampl
  • Amy Laysang
  • David Liu
  • Javier Lopez-Molina
  • Milly Milton
  • Albert Park
  • Marybeth A Pysz
  • Hui Shao
  • Brian Slingerland
  • Michael Torgov
  • Samuel A Williams
  • Orit Foord
  • Philip Howard
  • Jacek Jassem
  • Andrzej Badzio
  • Piotr Czapiewski
  • David H Harpole
  • Afshin Dowlati
  • Pierre P Massion
  • William D Travis
  • M Catherine Pietanza
  • J T Poirier
  • Charles M Rudin
  • Robert A Stull
  • Scott J Dylla
چکیده

The high-grade pulmonary neuroendocrine tumors, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), remain among the most deadly malignancies. Therapies that effectively target and kill tumor-initiating cells (TICs) in these cancers should translate to improved patient survival. Patient-derived xenograft (PDX) tumors serve as excellent models to study tumor biology and characterize TICs. Increased expression of delta-like 3 (DLL3) was discovered in SCLC and LCNEC PDX tumors and confirmed in primary SCLC and LCNEC tumors. DLL3 protein is expressed on the surface of tumor cells but not in normal adult tissues. A DLL3-targeted antibody-drug conjugate (ADC), SC16LD6.5, comprised of a humanized anti-DLL3 monoclonal antibody conjugated to a DNA-damaging pyrrolobenzodiazepine (PBD) dimer toxin, induced durable tumor regression in vivo across multiple PDX models. Serial transplantation experiments executed with limiting dilutions of cells provided functional evidence confirming that the lack of tumor recurrence after SC16LD6.5 exposure resulted from effective targeting of DLL3-expressing TICs. In vivo efficacy correlated with DLL3 expression, and responses were observed in PDX models initiated from patients with both limited and extensive-stage disease and were independent of their sensitivity to standard-of-care chemotherapy regimens. SC16LD6.5 effectively targets and eradicates DLL3-expressing TICs in SCLC and LCNEC PDX tumors and is a promising first-in-class ADC for the treatment of high-grade pulmonary neuroendocrine tumors.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Evaluation of Neuroendocrine and Proliferative Markers in Prostatic Adenocarcinomas

Background: Certain marker studies have practical importance in the biology of prostate cancer. The purpose of this study was to determine whether the quantification of certain neuroendocrine and proliferative markers obtained during transurethral resection or prostatectomy, would help in the prognostic evaluation of prostatic adenocarcinomas. Methods: The present study was performed on samples...

متن کامل

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

BACKGROUND Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in more than 80% of patients with small-cell lung cancer. We aimed to assess the safety and activity of rovalpituzumab tesirine in patients who progressed after one or more previous regimen. METHODS We c...

متن کامل

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies

Small cell lung cancer (SCLC) is a recalcitrant cancer for which no new treatments have been approved in over 30 years. While molecular subtyping now guides treatment selection for patients with non-small cell lung cancer and other cancers, SCLC is still treated as a single disease entity. Using model-based clustering, we found two major proteomic subtypes of SCLC characterized by either high t...

متن کامل

Docetaxel delivery using folate-targeted liposomes: in vitro and in vivo studies

Objective(s): Folate-targeted liposomes have been well considered in folate receptor (FR) overexpressing cells including MCF-7 and 4T1 cells in vitro and in vivo. The objective of this study is to design an optimum folate targeted liposomal formulations which show the best liposome cell uptake to tumor cells.Material and Methods: In this study, we prepared and characterized different targ...

متن کامل

Multifunctional MIL-S─CUR@FC nanoparticles: a targeted theranostic agent for magnetic resonance imaging and tumor targeted delivery of curcumin

Introduction: Noninvasive magnetic resonance imaging (MRI) and targeted drug delivery systems, usually referred to as theranostic agents, are being developed to enable detection, site-specific treatment, and long-term monitoring.   Materials and Methods: To elucidate the effects of coating on cellular uptake and biodistribution of n...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Science translational medicine

دوره 7 302  شماره 

صفحات  -

تاریخ انتشار 2015